P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 826-827
10.1097/01.hs9.0000846612.13339.9e